Respiratory tract infections and the fluoroquinolones of the latest generations


Cite item

Full Text

Abstract

This article presents data for the etiology of pneumonia and exacerbations of chronic bronchitis/chronic obstructive pulmonary disease. The spectrum of respiratory fluoroquinolones (levofloxacin, moxifloxacin), indications for their use, treatment regimens and dosage regimens are considered. The author presents own data for the long-term use of levofloxacin in the treatment of lower respiratory tract infections. Various schemes of levofloxacin use, including step-down therapy are expressed. The effectiveness of levofloxacin alone and in combination with carbapenems in the treatment of critically severe pneumonia is presented.

About the authors

V E Nonikov

V Nonikov

References

  1. Белоусов Ю.Б., Шатунов С.М. Антибактериальная химиотерапия. М., 2001. 473 с.
  2. Ноников В.Е., Маликов В.Е., Евдокимова С.А. и др. Антибиотики в пульмонологии // Кремлевская медицина - клинический вестник. 2005. № 1. С. 20-23.
  3. Практическое руководство по антиинфекционной химиотерапии / Под ред. Л.С. Страчунского, Ю.Б. Белоусова, С.Н. Козлова. Смоленск, 2007. 464 с.
  4. Bartlett J.G. 2005-2006 Pocket Book of Infectious Disease Therapy. Lippincott Williams & Wilkins. 2004. 349 с.
  5. Гилберт Д.Н., Моллеринг Р.С., Эллиопулос Д.М. и др. Сэнфордский спавочник: антимикробная терапия. М., 2009. 288 с.
  6. Wilson J, Estes L. Mayo Clinic Antimicrobial Therapy. Mayo Clinic Scientific Press 2008:324.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies